June 12, 2013Circulation Cardiovascular Quality and Outcomes
Risks and Benefits of Anticoagulation in Atrial Fibrillation
Key result
In outpatients with atrial fibrillation, oral anticoagulation use was 76% overall, increasing with higher stroke risk (53% to 80%, P<0.001) but decreasing with higher bleeding risk (81% to 73%, P<0.001).
Population
10 098 patients with atrial fibrillation from 174 community-based outpatient practices enrolled in 2010–2011…
Design
Cross-sectional
Authors
Discussion
Loading...
Member takes
Implication
AF outpatients receive OAC less often at high bleeding risk; supports guideline-directed stratification but leaves outcome impact open to prospective study.
Study Design
Type
Observational (n=10,098)
Multicenter
Yes
Structured PICO
P
Population
10 098 patients with atrial fibrillation from 174 community-based outpatient practices enrolled in 2010–2011 in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), mean age 73 years, 58% men.
O
Outcome
Rates of oral anticoagulation (OAC) use (warfarin or dabigatran) at study enrollment
In community-based outpatients with AF, oral anticoagulation use is driven by both stroke and bleeding risk, with high bleeding risk demonstrating consistently lower use of OAC regardless of stroke risk.
Cite This Study
Cullen et al. (2013) conducted an observational in Atrial Fibrillation (n=10,098). Oral anticoagulation (OAC) was evaluated on Rates of oral anticoagulation (OAC) use based on stroke and bleeding risk. In outpatients with atrial fibrillation, oral anticoagulation use was 76% overall, increasing with higher stroke risk (53% to 80%, P<0.001) but decreasing with higher bleeding risk (81% to 73%, P<0.001).